The Bull Case For Science Applications International (SAIC) Could Change Following Mixed Q3 Results And Capital Return Moves

Science Applications International Corporation recently reported third-quarter fiscal 2026 results showing lower year-on-year sales and earnings, while also updating full-year revenue guidance, completing a US$407.16 million share repurchase program, and declaring a US$0.37 per-share quarterly dividend payable on January 28, 2026. Taken together, the mix of softer quarterly performance, a slightly higher revenue outlook, and ongoing buybacks and dividends points to a company balancing near-term revenue pressure with confidence in its longer-term cash generation. We’ll now examine how the raised full-year revenue guidance and substantial completed buyback refine Science Applications International’s existing investment narrative. These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Science Applications International Investment Narrative RecapTo own Science Applications International, you need to believe that its mix of government IT modernization and mission-focused services can overcome budget pressures and contract delays. The latest quarter’s revenue and EPS decline underline those near-term headwinds, but the small revenue guidance lift suggests management sees some stabilization. For now, the most important catalyst remains execution on higher value modernization work, while the biggest risk is prolonged softness in federal spending and slower on-contract growth. The new data does not materially change that balance. Among the recent announcements, the completion of the US$407.16 million buyback, retiring about 7.83% of shares, is especially relevant. It tightens the share count at a time when earnings growth is modest, potentially amplifying per-share metrics if SAIC can sustain current profit levels. Combined with the steady US$0.37 quarterly dividend, the capital return story now sits alongside operational execution as a key focus for investors watching upcoming contract awards and funding decisions. Yet while capital returns look appealing, investors should be aware that persistent pressure on government IT budgets and contract timing could still... Read the full narrative on Science Applications International (it's free!)Science Applications International’s narrative projects $7.7 billion revenue and $344.8 million earnings by 2028. This requires 1.0% yearly revenue growth and an earnings decrease of about $54 million from $399.0 million today.Uncover how Science Applications International's forecasts yield a $113.38 fair value, a 13% upside to its current price.Exploring Other PerspectivesSAIC 1-Year Stock Price Chart Three fair value estimates from the Simply Wall St Community span about US$94.71 to US$196.04, showing how far apart individual views can be. When you set those against the ongoing risk of slower federal IT spending and delayed awards, it becomes clear why you may want to compare several perspectives before forming your own view on SAIC’s prospects.Explore 3 other fair value estimates on Science Applications International - why the stock might be worth 5% less than the current price!Build Your Own Science Applications International NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Science Applications International research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.Our free Science Applications International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Science Applications International's overall financial health at a glance.Looking For Alternative Opportunities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.The latest GPUs need a type of rare earth metal called Neodymium and there are only 36 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTech